MORGAN STANLEY PLC/CALL/EDWARDS LIFESCIENCES/140/0.1/20.12.24 | Real-time Bid/Ask 07:30:00 2024-05-20 EDT | ||
| 0.051 EUR / 0.084 EUR | +21.43% |
|
| Current month | +3.70% | ||
| 1 month | -22.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-05-20 | 0.051 | -8.93% |
| 24-05-17 | 0.056 | -8.20% |
| 24-05-16 | 0.061 | -3.17% |
| 24-05-15 | 0.063 | +10.53% |
| 24-05-14 | 0.057 | +9.62% |
Delayed Quote Börse Stuttgart
Last update May 20, 2024 at 07:22 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MB8GNB |
| ISIN | DE000MB8GNB3 |
| Date issued | 2023-07-07 |
| Strike | 140 $ |
| Maturity | 2024-12-20 (215 Days) |
| Parity | 10 : 1 |
| Emission price | 0.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.31 € |
|---|---|
| Lowest since issue | 0.044 € |
| Spread | 0.033 € |
| Spread % | 39.29% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
89.14
USD
Average target price
95.9
USD
Spread / Average Target
+7.59%
- Stock Market
- Warrants
- Warrant
